Julie-anne E. Tanner

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.

Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.

Journal: Translational psychiatry

Published: May 31, 2022

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.

Journal: The pharmacogenomics journal

Published: December 03, 2021

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.

Journal: Translational psychiatry

Published: June 11, 2021

Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes.

Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes.

Journal: Clinical and translational science

Published: April 29, 2021

Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective.

Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective.

Journal: Pharmacogenomics

Published: April 18, 2020

Economic Burden of Depression and Associated Resource Use in Manitoba, Canada.

Economic Burden of Depression and Associated Resource Use in Manitoba, Canada.

Journal: Canadian journal of psychiatry. Revue canadienne de psychiatrie

Published: December 15, 2019

Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications.

Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications.

Journal: ClinicoEconomics and outcomes research : CEOR

Published: August 03, 2019

Adequate evidence to support improved outcomes in depression by primary care physicians compared to psychiatrists when using combinatorial pharmacogenomics.

Adequate evidence to support improved outcomes in depression by primary care physicians compared to psychiatrists when using combinatorial pharmacogenomics.

Journal: Journal of psychiatric research

Published: October 17, 2018

Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists.

Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists.

Journal: Journal of psychiatric research

Published: May 02, 2018

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Journal: Pharmacogenetics and genomics

Published: December 13, 2017

Variation in CYP2A6 Activity and Personalized Medicine.

Variation in CYP2A6 Activity and Personalized Medicine.

Journal: Journal of personalized medicine

Published: October 07, 2017

Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Journal: Pharmacogenetics and genomics

Published: February 10, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026